Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303

Nancy L. Bartlett*, Wyndham H. Wilson, Sin Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi D. Pederson, Mei Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha M. Reddy, Jane N. Winter, Julie E. Chang, Ajay K. Gopal, Amy ChadburnSusan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schoder, Andrew D. Zelenetz, John P. Leonard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Fingerprint

Dive into the research topics of 'Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303'. Together they form a unique fingerprint.

Medicine & Life Sciences